MedTrace Logo

Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis

NCT03209219 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2021-02-23

No results posted yet for this study

Summary

Brief summary: This study compares the long-term efficacy and safety of interferon (IFN) α2a and cyclosporine (cyclosporin A, CsA) following suppression of acute attack by high-dose oral glucocorticosteroid in patients with refractory Behçet's uveitis (BDU). Half of the participants will receive IFNα2a while the other half will receive CsA.

Conditions

  • Behçet Disease
  • Uveitis

Interventions

DRUG

Interferon Alfa-2A

3×10\^6 IU， subcutaneous or intramuscular injection, qd for × 4 weeks, and qod thereafter

DRUG

Cyclosporine Pill

100mg， oral, bid

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-30
Primary Completion
2020-08-31
Completion
2021-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03209219 on ClinicalTrials.gov